Child's Nervous System

, Volume 35, Issue 12, pp 2405–2409 | Cite as

Non-convulsive status epilepticus in two patients with tuberous sclerosis

  • Yuksel ErdalEmail author
  • Alper Alnak
  • Ozgur Oztop
  • Pınar Tekturk
  • Zuhal Yapici
Case Report


Tuberous sclerosis (TSC) is an autosomal dominantly inherited genetic disorder that chiefly affects the central nervous system, along with the other multiple systems. While phenomenology and symptom severity may vary greatly from one individual to another, the most common neurological presentation is epilepsy, which may be refractory in a considerable number of patients. Convulsive SE is seen frequently in TSC patients due to the high ratio of refractory seizures in well-studied cohorts. Status epilepticus (SE) is a life-threating condition and requires urgent medical care. Non-convulsive status epilepticus (NCSE) is an epileptic state with no convulsive seizures but impaired consciousness and corresponding electrophysiological findings. Due to its heterogeneity of clinical features, it is generally hard to recognize, and thus difficult to treat promptly. The relationship between TSC and NCSE is a relatively less emphasized issue in the literature. Here, we present two cases of TSC with NCSE with a view to increasing clinicians’ awareness of the association between refractory epilepsy and NCSE.


Tuberous sclerosis Status epilepticus Non-convulsive status epilepticus mTOR inhibitors 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Akman CI (2010) Nonconvulsive status epilepticus and continuous spike and slow wave of sleep in children. Semin Pediatr Neurol 17(3):155–162CrossRefGoogle Scholar
  2. 2.
    Almaabdi KH, Alshehri RO, Althubiti AA et al (2014) Intravenous methylprednisolone for intractable childhood epilepsy. Pediatr Neurol 50:334–336CrossRefGoogle Scholar
  3. 3.
    Chu-shore CJ, Major P, Camposano S, Muzykewicz D, Thiele EA (2011) The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 51(7):1236–1241CrossRefGoogle Scholar
  4. 4.
    Crino PB (2016) The mTOR signalling cascade: paving new roads to cure neurological disease. Nat Rev Neurol 12(7):379–392CrossRefGoogle Scholar
  5. 5.
    Curatolo P, Jóźwiak S, Nabbout R (2012) Management of epilepsy associated with tuberous sclerosis complex ( TSC ): clinical recommendations. Eur J Paediatr Neurol 16(6):582–586CrossRefGoogle Scholar
  6. 6.
    Curatolo P, Moavero R, De Vries PJ (2015) Neurological and neuropsychiatric aspects of tuberous. Lancet Neurol 14(7):733–745CrossRefGoogle Scholar
  7. 7.
    Curatolo P, Nabbout R, Lagae L et al (2018) Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol 22(5):738–748CrossRefGoogle Scholar
  8. 8.
    French JA, Lawson JA, Yapici Z et al (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis ( EXIST-3 ): a phase 3, randomised , double-blind , placebo-controlled study. Lancet 6736(16):1–11Google Scholar
  9. 9.
    Jafarpour S, Stredny CM, Piantino J, Chapman KE (2018) Baseline and outcome assessment in pediatric status epilepticus. Seizure 68:52–61CrossRefGoogle Scholar
  10. 10.
    Kuki I, Kawawaki H, Okazaki S, Ehara E, Yoshida Y, Kunihiro N, Matsusaka Y (2018) Efficacy and safety of everolimus in patients younger than 12 months with congenital subependymal giant cell astrocytoma. Brain and Development 40(5):415–420CrossRefGoogle Scholar
  11. 11.
    Maganti R, Gerber P, Drees C, Chung S (2008) Nonconvulsive status epilepticus. Epilepsy Behav 12:572–586CrossRefGoogle Scholar
  12. 12.
    Pera MC, Randazzo G, Masnada S et al (2015) Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy. Funct Neurol 30(3):173–179PubMedPubMedCentralGoogle Scholar
  13. 13.
    Savini MN, Mingarelli A, Vignoli A et al (2018) Ictal signs in tuberous sclerosis complex : Clinical and video-EEG features in a large series of recorded seizures. Epilepsy Behav 85:14–20CrossRefGoogle Scholar
  14. 14.
    Schubert-bast S, Rosenow F, Martin K, Reif PS, Kieslich M, Strzelczyk A (2018) The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: current evidence and future perspectives. Epilepsy Behav 91:94–98CrossRefGoogle Scholar
  15. 15.
    Shehata HS, Abdel Ghaffar HM, Nasreldin M, Elmazny A, Abdelalim A, Sabbah A, Shalaby NM (2017) Clinical patterns and outcomes of status epilepticus in patients with tuberous sclerosis complex. Ther Clin Risk Manag 13:779–785CrossRefGoogle Scholar
  16. 16.
    Trinka E, Cock H, Hesdorffer D et al (2015) A definition and classification of status epilepticus–report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 56(10):1515–1523CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologyHealth Science University, Istanbul Training and Research HospitalIstanbulTurkey
  2. 2.Department of Child and Adolescent PsychiatryIstanbul Faculty of Medicine, Istanbul UniversityIstanbulTurkey
  3. 3.Department of NeurologyFaculty of Medicine, Koc UniversityIstanbulTurkey
  4. 4.Division of Child Neurology, Department of NeurologyIstanbul Faculty of Medicine, Istanbul UniversityIstanbulTurkey

Personalised recommendations